“A room full of healers.” This is how Larry Norton, Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering, described the feel of the auditorium during the 4th Advanced Breast Cancer [more]
Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports [more]
‘Value’ is the latest buzzword in cancer: value-based pricing, delivering value for cancer care, enhancing the value offering for cancer technologies… It makes sense, as focusing on the value of interventions we invest in is [more]
Could tailoring treatments to broad taxonomies work where targeting individual – or even multiple – genetic mutations has not? A growing number of researchers working on specific tumour types and/or across tumours believe this integrative [more]
Most solid tumours will prove fatal if they are not treated with surgery and/or radiotherapy and medical therapies. But evidence is building to show that treating the primary may raise the risk of metastatic spread. [more]
Legislators and policy makers could do a lot more to promote cancer research if they understood that improving treatment strategies is not all about new drugs, and that patients and health budgets pay a high [more]
Cancer patients are put at risk unless the surgeons who operate on them understand the principles of the disease, work closely with other oncology disciplines, and know which patients need to be referred to high-volume [more]
When it comes to developing capacity for tackling cancer, all too often the best intentions founder because key players are not engaged, costings are not done, sustainable funding is not secured, visiting experts dispense their [more]
The need to give greater weight to patients’ own assessments of treatment impacts is increasingly accepted in principle. Putting it into practice will require a lot of hard work, developing tools that work for specific [more]
‘Survivorship’ is a rapidly growing field of research, as more cancer patients live longer, and require different types of support to get their lives back on track. Typically such research has been disconnected from clinical [more]
A professor of haematology, specialising in bone marrow transplants and leukaemia, with a career that has spanned clinical practice, research, policy making and now political office – Agnès Buzyn has an unrivalled breadth of experience [more]